The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Metabolic reprogramming confers resistance to lenalidomide in multiple myeloma
Wee Joo Chng, MB ChB, MRCP, MRCPath, PhD, National University of Singapore, Singapore, discusses the role of NSD2, a histone methyltransferase, in resistance to lenalidomide in patients with multiple myeloma. Patients with a t(4;14) translocation tend to have high-risk multiple myeloma, leading to overexpression of NSD2 and metabolic dysregulation. Modulating the metabolic pathway may subsequently enhance sensitivity to existing treatments such as lenalidomide and pomalidomide. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
